2022-RA-945-ESGO Antitumour activity of dostarlimab by PD-L1 and tumour mutation burden in patients with mismatch repair deficient and proficient tumours in the GARNET trial

Abstract

with mismatch repair deficient (dMMR) recurrent/advanced endometrial cancer (EC) that has progressed on or after platinum-based chemotherapy or solid tumours that have progressed on or after prior treatment, with no satisfactory alternative treatment options. We report a post hoc analysis of antitumour activity by PDL1 expression and tumour mutational burden (TMB) in patients with dMMR and MMR proficient (MMRp) solid tumours in the GARNET trial.